I've found this to be a not uncommon way of thinking by those...

First 336 Last

Share
Profile

Follow
akathaddeus

152 Posts.

143

16/06/22

08:32

Post #: 62026755
Share

Originally posted by platypusasx: ↑

1- It seems to me the principal investigator and company as a whole are very "high horse" and by the book. I think this principal investigator the company has chosen has done a very poor job. Additionally, this whole ethical issue they have with incentives gets me thinking if it was another investigator there's a good chance they may not have had these personal ethical issues and shareholder value may not have been destroyed.
2- I also think the way the company reports may not be optimal for microcaps. It is common knowledge that microcaps largely attract the retail end of the market and retail investors are generally short-sited and required sustained updates/ announcement or they will go looking for the next 'sugar rush'. The companies approach and view towards only announcing certain things and how they view material information isn't shared with some other companies. I see lots of news flow and announcements elsewhere which may not always be the most significant and new information but it prevents the retail market from fleeing.
The way the board spoke about announcements and communication etc at the AGM reflects their views which are not ideal when the majority of the holding is retail.

I'm interested in others views on these two points.

Expand

I've found this to be a not uncommon way of thinking by those who are technical specialists. We've all received the types of dogmatic perspectives from engineers, programmers, scientists etc... particularly those with deep specilisations. They are functionally highly skilled but life is easiest if rules are followed conservatively. That's not necessarily a bad thing when it comes to safety.

The situation will be different after a safe outcome. Incentives is then approvable even in Australia in IBX's case. Given a lack of safety concerns, the low incidence of disease and lack of therapeutic value are relevant factors.

The board here consists of technical people (biotech, compliance, technical sales, a lawyer and an accountant) and so conservative rule following is going to be the norm. IBX needs a commercially orientated chair to look after shareholders and one who understands that the corporate watchdog also place value on transparency. Markets function better when fully informed... and money comes from commercial thought.

IBX Price at posting: 2.8¢ Sentiment: Hold Disclosure: Held
13 Upvote

2 Great analysis

Reply